Reviewing Seres Therapeutics Inc. (MCRB)’s and Avid Bioservices Inc. (NASDAQ:CDMO)’s results

Since Seres Therapeutics Inc. (NASDAQ:MCRB) and Avid Bioservices Inc. (NASDAQ:CDMO) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seres Therapeutics Inc. 4 0.02 41.01M -2.34 0.00
Avid Bioservices Inc. 5 0.00 42.61M -0.17 0.00

Table 1 highlights Seres Therapeutics Inc. and Avid Bioservices Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 demonstrates the return on equity, net margins and return on assets of Seres Therapeutics Inc. and Avid Bioservices Inc.

Net Margins Return on Equity Return on Assets
Seres Therapeutics Inc. 1,127,639,683.24% 235.9% -81.2%
Avid Bioservices Inc. 810,076,045.63% -16.4% -11.1%

Risk & Volatility

Seres Therapeutics Inc. has a beta of 2 and its 100.00% more volatile than Standard & Poor’s 500. Competitively, Avid Bioservices Inc. is 185.00% more volatile than Standard & Poor’s 500, because of the 2.85 beta.


The Current Ratio of Seres Therapeutics Inc. is 1.6 while its Quick Ratio stands at 1.6. The Current Ratio of rival Avid Bioservices Inc. is 2.2 and its Quick Ratio is has 1.9. Avid Bioservices Inc. is better equipped to clear short and long-term obligations than Seres Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for Seres Therapeutics Inc. and Avid Bioservices Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Seres Therapeutics Inc. 0 0 0 0.00
Avid Bioservices Inc. 0 0 2 3.00

Competitively Avid Bioservices Inc. has a consensus target price of $9.5, with potential upside of 77.57%.

Institutional and Insider Ownership

Seres Therapeutics Inc. and Avid Bioservices Inc. has shares owned by institutional investors as follows: 61.9% and 49%. About 0.4% of Seres Therapeutics Inc.’s share are owned by insiders. Competitively, Avid Bioservices Inc. has 11.62% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Seres Therapeutics Inc. -9% -7.46% -55.32% -55.46% -62.76% -39.6%
Avid Bioservices Inc. 1.25% 6.23% 39.66% 71.43% 18.9% 58.05%

For the past year Seres Therapeutics Inc. had bearish trend while Avid Bioservices Inc. had bullish trend.


On 7 of the 11 factors Avid Bioservices Inc. beats Seres Therapeutics Inc.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.